The CV safety of a lower dose of liraglutide (1.8 mg, Victoza, Novo Nordisk) in people with T2D was established in the Liraglutide Effect and Action in Diabetes: Evaluation of CV Outcome Results (LEADER) study, showing a 13% reduction in major CV events over an average of 3.8 years [44]
In trials, dosing was administered as a once-weekly subcutaneous injection, with gradual dose titration to minimise gastrointestinal side effects whilst allowing the body to adapt
Store lyophilized at -20C
Start by aiming for the same bedtime and wake-up time every day, even on weekends
Harris uses a start low, go slow dosing approach to help minimize discomfort and support a smooth experience
No claims are made or implied regarding weight loss, metabolic benefits, therapeutic results, or human use